OBJECTIVES: The regulatory changes in Korea during the national economic crisis 10 years ago and in the current global recession were analyzed to understand the characteristics of deregulation in labor policies. METHODS: Data for this study were derived from the Korean government's official database for administrative regulations and a government document reporting deregulation. RESULTS: A great deal of business-friendly deregulation took place during both economic crises. Occupational health and safety were the main targets of deregulation in both periods, and the regulation of employment promotion and vocational training was preserved relatively intact. The sector having to do with working conditions and the on-site welfare of workers was also deregulated greatly during the former economic crisis, but not in the current global recession. CONCLUSIONS: Among the three main areas of labor policy, occupational health and safety was most vulnerable to the deregulation in economic crisis of Korea. A probable reason for this is that the impact of deregulation on the health and safety of workers would not be immediately disclosed after the policy change.
Cost Control/legislation & jurisprudence/methods ; *Economic Recession ; Employment/*economics/legislation & jurisprudence/statistics & numerical data ; Government Regulation ; Humans ; Occupational Health/*legislation & jurisprudence/statistics & numerical data ; Public Policy ; Republic of Korea ; Workplace/economics/legislation & jurisprudence/standards

For over 100 years, controlled human infection (CHI) studies have been performed to advance the understanding of the pathogenesis, treatment and prevention of infectious diseases. This methodology has seen a resurgence, as it offers an efficient model for selecting the most promising agents for further development from available candidates. CHI studies are utilised to bridge safety and immunogenicity testing and phase II/III efficacy studies. However, as this platform is not currently utilised in Asia, opportunities to study therapeutics and vaccines for infections that are important in Asia are missed. This review examines the regulatory differences for CHI studies between countries and summarises other regulatory differences in clinical trials as a whole. We found that the regulations that would apply to CHI studies in Singapore closely mirror those in the United Kingdom, and conclude that the regulatory and ethical guidelines in Singapore are compatible with the conduct of CHI studies.
Asia ; Clinical Trials as Topic ; economics ; standards ; Communicable Disease Control ; Communicable Diseases ; epidemiology ; Cost-Benefit Analysis ; Ethics, Medical ; Health Policy ; Humans ; Infectious Disease Medicine ; legislation & jurisprudence ; standards ; Quarantine ; Research Design ; standards ; Singapore ; United Kingdom